A new COVID-19 treatment aimed at decreasing hospitalizations and preventing deaths is becoming more widely used in the St. Louis area. The treatment, called monoclonal antibody therapy has been used on over 500 patients in St. Louis and is offered at four BJC locations. Dr. Maya Jerath is co-leading the monoclonal antibody treatment at BJC and said patients 65 and older or those with comorbidities like obesity, heart disease and compromised immune system see the biggest benefits. If treated early, Jerath said monoclonal antibodies can reduce hospitalizations by 70%.
Dr. Maya Jerath is co-leading the monoclonal antibody treatment at BJC